BioCentury | Jul 31, 1995
Analyst Picks & Changes

Analyst picks & changes

...sales of NXTR's AmBisome liposomal amphotericin B were up 40 percent at $14.2 million, topping S.G. Warburg...
BioCentury | Feb 27, 1995
Analyst Picks & Changes

Analyst picks & changes

...Argus Pharmaceuticals Inc. (ARGS) Robert Faulkner of S.G. Warburg said the merger between ARGS, Triplex Pharmaceutical Corp...
BioCentury | Jan 16, 1995
Analyst Picks & Changes

Analyst picks & changes

...Regeneron Pharmaceuticals Inc. (REGN) Robert Faulkner of S.G. Warburg raised REGN to "hold" from "reduce" following the...
BioCentury | May 16, 1994
Analyst Picks & Changes

Analyst picks & changes

...Genentech Inc. S.G. Warburg analyst Kevin Wilson downgraded Genentech Inc. to "add" from "buy" on the basis...
BioCentury | Mar 21, 1994
Analyst Picks & Changes

Analyst picks & changes

...NeXagen Inc. (NXGN) S.G. Warburg analyst Kevin Wilson initiated coverage with a "buy" and a one-year price...
BioCentury | Sep 27, 1993
Finance

Analyst picks & changes

...flow to repurchase shares at the rate of $250 million per year. Kevin Wilson of S.G. Warburg...
BioCentury | Sep 20, 1993
Clinical News

Provir antiviral data

...conducted at the University of Rochester further demonstrated the product's safety, researchers said at the S.G. Warburg...
BioCentury | Aug 16, 1993
Finance

Dampening expectations

...patients treated at doses of 3 µg/kg and above had anti-CNTF antibodies. Can't draw conclusions S.G. Warburg...
Items per page:
1 - 8 of 8
BioCentury | Jul 31, 1995
Analyst Picks & Changes

Analyst picks & changes

...sales of NXTR's AmBisome liposomal amphotericin B were up 40 percent at $14.2 million, topping S.G. Warburg...
BioCentury | Feb 27, 1995
Analyst Picks & Changes

Analyst picks & changes

...Argus Pharmaceuticals Inc. (ARGS) Robert Faulkner of S.G. Warburg said the merger between ARGS, Triplex Pharmaceutical Corp...
BioCentury | Jan 16, 1995
Analyst Picks & Changes

Analyst picks & changes

...Regeneron Pharmaceuticals Inc. (REGN) Robert Faulkner of S.G. Warburg raised REGN to "hold" from "reduce" following the...
BioCentury | May 16, 1994
Analyst Picks & Changes

Analyst picks & changes

...Genentech Inc. S.G. Warburg analyst Kevin Wilson downgraded Genentech Inc. to "add" from "buy" on the basis...
BioCentury | Mar 21, 1994
Analyst Picks & Changes

Analyst picks & changes

...NeXagen Inc. (NXGN) S.G. Warburg analyst Kevin Wilson initiated coverage with a "buy" and a one-year price...
BioCentury | Sep 27, 1993
Finance

Analyst picks & changes

...flow to repurchase shares at the rate of $250 million per year. Kevin Wilson of S.G. Warburg...
BioCentury | Sep 20, 1993
Clinical News

Provir antiviral data

...conducted at the University of Rochester further demonstrated the product's safety, researchers said at the S.G. Warburg...
BioCentury | Aug 16, 1993
Finance

Dampening expectations

...patients treated at doses of 3 µg/kg and above had anti-CNTF antibodies. Can't draw conclusions S.G. Warburg...
Items per page:
1 - 8 of 8